Aug 03, 2012 - 4:34 pm
I went with John to his doctor’s appointment yesterday and I brought up his thyroid/medication levels and questioned his need to stay on those meds. The oncologist agreed it was reasonable “to stop the medication for six weeks and see where we are at that time.” So John has one less drug to take for now.
He also had a CT scan. As most of you know, John is on the Votrient/BMS 936558 (MDX 1106) trial and his previous scan on 6/20/12 showed a 31% reduction in tumor burden. It appears that his improvement is continuing though I don’t have a percentage of reduction yet. The percentage number comes days after the scan from the clinical trial sponsors. I’ll post that when it comes.
Two of the impressions are noted below:
One other impression caused us some concern, though his doctor isn’t too worried about it. Said it could be side effect of medication and something we will watch. Jeff (Medscan man) - any thoughts?
“4 mm focus of arterial enhancement in segment 6 of the liver which is hypodense on
Appreciate all your support.
10/14/11 – Diagnosed with Kidney cancer clear cell/grade 4/stage 4 – with sarcomatoid features and lung mets; also has soft tissue mass in shoulder area and pelvic area.
Symptoms: weight loss followed by cough
Treatments to date:
5/10/2012 – Began MDX1106/Votrient trial
6/20/2012 – CT scan showed 31% reduction in tumor burden